[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Anzhen Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":606},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,42,66,88,110,132,156,178,206,229,252,274,308,335,358,383,404,424,442,464,492,514,536,560,584],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100650685","micro-nanoplastic-exposure-and-coronary-microcirculatory-dysfunction-as-well-as-cardiovascular-outcomes-100650685",false,"NCT07748767","Micro-nanoplastic Exposure and Coronary Microcirculatory Dysfunction as Well as Cardiovascular Outcomes","Association of Micro-Nanoplastic Exposure With Coronary Microvascular Dysfunction and Subsequent Cardiovascular Outcomes: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18;\n* Patients with clinical indications for undergoing invasive coronary angiography and coronary functional assessment (including fractional flow reserve \\[FFR\\], CFR, and IMR);\n* Voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* The surgeon (or attending physician) determines that the patient is not suitable for or cannot tolerate a coronary physiological examination;\n* Intraoperative coronary angiography reveals a stenosis of\\>90% in any non-left main coronary artery lumen or a stenosis of\\>50% in the left main coronary artery lumen;\n* Left ventricular ejection fraction \\\u003C35% or cardiogenic shock or cardiac arrest;\n* Previous history of invasive procedures\u002Ftreatments;\n* Active inflammatory diseases;\n* Connective tissue disease;\n* History of malignant tumors;\n* Expected lifespan \\\u003C2 years;\n* Pregnancy or lactation;\n* Subjects who refuse to comply with the pollution control measures set in this study;\n* Currently participating in other interventional clinical trials.","ALL","18 Years",{"count":20,"type":21},184,"ESTIMATED","2 Years","OBSERVATIONAL","With strict quality control procedures applied throughout microplastic testing, this study will assess the association between baseline circulating micro-nanoplastic exposure and coronary microvascular dysfunction, as well as subsequent long-term cardiovascular outcomes.",[26,27,28,29],"Coronary Microvascular Dysfunction (CMD)","Microplastic Exposure","Nanoplastics","MACE","NOT_YET_RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":21},"2027-01-01",{"date":38,"type":21},"2029-12-31",{"name":40,"class":41},"Beijing Anzhen Hospital","OTHER",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100618503","digital-remote-management-for-care-and-continuous-optimization-versus-usual-care-to-reduce-risk-of-atherosclerotic-cardiovascular-diseases-digicare-ascvd-100618503","NCT07332468","Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-preASCVD)","Inclusion Criteria:\n\n1. 10-year ASCVD risk ≥ 10%, calculated using the China-PAR risk prediction model\n2. Adultd aged ≥ 35 years\n3. Able to use a smartphone (or assisted by family) and agrees to remote management\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. History of acute myocardial infarction, stroke, heart failure, malignant arrhythmia, or prior percutaneous coronary intervention or coronary artery bypass grafting surgery\n2. Moderate to severe hepatic dysfunction (Child-Pugh class B-C)\n3. CKD stages 4-5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m²) or on dialysis\n4. Chronic obstructive pulmonary disease requiring ongoing home oxygen therapy or chronic oral steroid therapy as an outpatient\n5. Pregnant, planning to become pregnant within the next 12 months\n6. Life expectancy \\\u003C12 months (e.g., advanced malignancy, etc.);\n7. Cognitive impairment or communication disorder.","35 Years",{"count":50,"type":21},564,"INTERVENTIONAL",[53],"NA","The DigiCare-preASCVD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated whether digital remote management is superior to usual care in reducing risk of atherosclerotic cardiovascular diseases and improving blood pressure control, glycemic control, lipids control, medication compliance and lifestyle.",[56],"Atherosclerotic Cardiovascular Diseases","RECRUITING","2026-08-16",{"date":31,"type":34},{"date":61,"type":34},"2026-02-25",{"date":63,"type":21},"2028-04",{"name":40,"class":41},5,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":51,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100650255","phase-2-selinexor-daratumumab-and-dexamethasone-xdd-for-light-chain-cardiac-amyloidosis-100650255","NCT07743957","Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis","Selinexor Combined With Daratumumab and Dexamethasone (XDd) for the Treatment of Patients With Advanced Light-Chain Cardiac Amyloidosis: A Prospective, Multicenter, Phase II Clinical Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Confirmed systemic light-chain amyloidosis, meeting both of the following:\n\n  1. Tissue biopsy confirms amyloid deposition, and the amyloid precursor protein is immunoglobulin light chain or heavy-light chain. Pathologic evidence includes at least one of the following: Congo red staining positive with apple-green birefringence under polarized light microscopy; Light-chain restricted expression demonstrated by immunohistochemistry, immunofluorescence, or immunoelectron microscopy, or mass spectrometry confirming the precursor protein as immunoglobulin light chain; Electron microscopy showing nonbranching, rigid, randomly arranged fibrils with a diameter of 8 to 14 nm.\n  2. Evidence of monoclonal immunoglobulin or free light chain in serum or urine, or detection of monoclonal plasma cells\u002FB cells in bone marrow examination.\n* Clinical manifestations, physical examination, laboratory tests, or imaging studies confirm involvement of one or more organs, with mandatory cardiac involvement. Cardiac involvement is defined as either:\n\n  1. Mean ventricular wall thickness \\> 12 mm on echocardiography, with other cardiac diseases excluded; or\n  2. NT-proBNP \\> 332 ng\u002FL in the absence of renal insufficiency and atrial fibrillation.\n* Mayo 2004 stage IIIa or IIIb disease, including newly diagnosed and relapsed\u002Frefractory patients.\n* Measurable disease in light-chain amyloidosis, defined by at least one of the following:\n\n  1. Serum monoclonal protein ≥ 0.5 g\u002FdL by serum protein electrophoresis and immunofixation performed by the central laboratory;\n  2. Serum free light chain ≥ 50 mg\u002FL with an abnormal kappa\u002Flambda ratio; or\n  3. Difference between involved and uninvolved free light chains (dFLC) ≥ 50 mg\u002FL. Note: Urine Bence Jones proteinuria alone is not sufficient to define measurable disease for eligibility.\n* Not pregnant or breastfeeding. Men and women of childbearing potential must agree to use appropriate contraception before treatment, during treatment, during any treatment interruption, and for 4 weeks after treatment completion.\n* Written informed consent has been signed by the participant. If the participant is unable to sign because of their medical condition, informed consent may be signed by a legal guardian or immediate family member.\n\nExclusion Criteria:\n\n* Active hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, or other acquired or congenital immunodeficiency disorders.\n* Baseline peripheral neuropathy or neuropathic pain of grade ≥ 2 according to NCI CTCAE v4.0.\n* Major surgery within 30 days before enrollment.\n* Epilepsy requiring medication, dementia, or other psychiatric conditions that prevent understanding of or compliance with the study protocol.\n* Any severe physical or psychiatric illness that may interfere with participation in this clinical study.\n* Any other condition that the investigator considers unsuitable for enrollment.",{"count":74,"type":21},63,[76],"PHASE2","The goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac amyloidosis. The main questions it aims to answer are:\n\nDoes XDd regimen achieve hematologic complete response in patients with advanced light-chain cardiac amyloidosis? Does XDd regimen improve cardiac response, organ response, progression-free survival, overall survival, quality of life, and safety?",[79],"Light-chain Cardiac Amyloidosis","2026-08-12",{"date":82,"type":34},"2026-08-13",{"date":84,"type":21},"2026-07-13",{"date":86,"type":21},"2028-06-01",{"name":40,"class":41},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":51,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100617257","safety-and-effectiveness-of-catheter-ablation-for-atrial-fibrillation-with-intracranial-hemorrhage-safer-af-100617257","NCT07316270","SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Between 14 Days and 12 Months After Spontaneous Intracranial Hemorrhage (intraparenchymal or intraventricular hemorrhage, and subdural hematoma)\n3. Able to Access Intracranial Hemorrhage Imaging Data\n4. ECG indicating the presence of atrial fibrillation\n5. CHA₂DS₂-VA Score ≥ 2\n6. Willing to undergo randomization and able to complete follow-up as required\n\nExclusion Criteria:\n\n1. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.)\n2. Fully dependent (modified Rankin Scale \\[mRS\\] score \\> 4)\n3. Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg)\n4. Presence of uncontrolled active bleeding\n5. Presence of active infection requiring antibiotic treatment\n6. End-stage renal failure or receiving dialysis treatment\n7. Presence of liver failure\n8. Untreated coronary artery disease with indication for revascularization\n9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography\n10. Expected life expectancy \\\u003C 1 year (e.g., advanced malignant tumors, etc.)\n11. Pregnant, lactating, or women planning to become pregnant\n12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study\n13. Other conditions deemed unsuitable for participation in the study by the investigators",{"count":95,"type":21},646,[53],"SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracranial hemorrhage.",[99,100],"AF - Atrial Fibrillation","Intracranial Hemorrhage, Spontaneous","2026-08-05",{"date":103,"type":34},"2026-08-07",{"date":105,"type":34},"2026-05-06",{"date":107,"type":21},"2030-01",{"name":40,"class":41},7,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100604452","ventricular-tachycardiaa-registry-study-100604452","NCT07149701","Ventricular Tachycardia：A Registry Study","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study.\n* Structural heart disease diagnosed according to current clinical guidelines.\n* Willing and able to provide written informed consent.\n* Willing to comply with the study follow-up schedule.\n\nExclusion Criteria:\n\n* Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances).\n* Idiopathic ventricular tachycardia without evidence of structural heart disease.\n* Cardiac surgery within 60 days before enrollment.\n* Severe infectious diseases (e.g., septic shock or sepsis).\n* Severe coagulation disorders, including platelet count \\\u003C50 × 10⁹\u002FL or disseminated intravascular coagulation.\n* Participation in another interventional clinical study that may interfere with this registry.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation.",{"count":117,"type":21},1000,"1 Year","Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.",[121,122],"Ventricular Tachycardia (VT)","Structural Heart Disease","2026-07-27",{"date":125,"type":34},"2026-07-29",{"date":127,"type":34},"2025-10-14",{"date":129,"type":21},"2029-12-01",{"name":40,"class":41},1,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":131},"100641153","modifiable-risk-factors-for-cognitive-dysfunction-in-patients-with-coronary-heart-disease-100641153","NCT07657624","Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease","Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of coronary heart disease (meeting at least one of the following):\n\n   * Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;\n   * Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;\n   * Objective evidence of myocardial ischemia or typical clinical symptoms\n3. Completion of standardized neuropsychological assessment during hospitalization\n4. Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments\n5. Provision of signed written informed consent\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia.\n2. History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.\n3. Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n4. Pregnancy or breastfeeding.",{"count":140,"type":21},2352,"This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.This study is led by the National Clinical Research Center for Cardiovascular Diseases and invited to be carried out by several Chinese centers including Beijing Anzhen Hospital.",[143,144],"Coronary Heart Disease","Cognitive Impairment, Mild",[146,147,143],"Risk Factors","Cognitive Impairment","2026-07-14",{"date":150,"type":34},"2026-07-15",{"date":152,"type":34},"2025-06-30",{"date":154,"type":21},"2031-05-01",{"name":40,"class":41},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":51,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100646361","wearable-device-assisted-remote-management-to-improve-prognosis-in-patients-with-acute-heart-failure-complicated-by-atrial-fibrillation-warm-hf-trial-stage-2-100646361","NCT07687862","Wearable Device-Assisted Remote Management to Improve Prognosis in Patients With Acute Heart Failure Complicated by Atrial Fibrillation: WARM-HF Trial (Stage 2)","A Researcher-initiated, Prospective, Open-label, Randomized Controlled Trial With a Parallel Design to Investigate the Prognostic Impact of Wearable Device-assisted Remote Management in Patients With Acute Heart Failure Complicated by Atrial Fibrillation","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Subjects diagnosed with acute decompensated heart failure (ADHF) :\n\n1)Heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40%; 2)New York Heart Association (NYHA) functional class II-IV; 3)NT-proBNP \\> 2500 pg\u002FmL or BNP \\> 600 pg\u002FmL 3. Atrial fibrillation (AF) diagnosed during hospitalization (documented AF episode lasting \\> 30 seconds on electrocardiogram \\[ECG\\] within the past 12 months)\n\nExclusion Criteria:\n\n1. Intolerance to heart failure pharmacotherapy;\n2. Severe anemia or untreated thyroid disease;\n3. ST-segment elevation myocardial infarction within 3 months;\n4. Known complex congenital heart disease; infiltrative cardiomyopathy (such as cardiac amyloidosis, sarcoidosis, lymphoma, or endomyocardial fibrosis); myocarditis; constrictive pericarditis; cardiac tamponade; hypertrophic cardiomyopathy; stress cardiomyopathy; or uncorrected primary valvular heart disease requiring surgical interventions;\n5. Prior major cardiac surgery or mechanical circulatory support, or planned within 6 months, including coronary artery bypass grafting, cardiac valve repair or replacement, ventricular assist device or mechanical circulatory support device implantation, and heart transplantation;\n6. Existing pacemaker or planned pacemaker implantation;\n7. Contraindications to wearing a smartwatch (such as limb disability or known allergy to rubber\u002Fmetal materials);\n8. Inability to access the Internet or lack of proficiency in operating smart devices.",{"count":164,"type":21},818,[53],"With the advancement of wearable technology, continuous non-invasive monitoring of vital signs, arrhythmia burden, and physical status has become increasingly feasible. Devices such as smartwatches and electrocardiogram (ECG) straps can provide real-time physiological data, offering new opportunities for remote and proactive disease management. Despite the growing availability of such real-time data, the complex interaction between atrial fibrillation (AF) and heart failure (HF) necessitates highly personalized management. However, there remains a lack of high-quality clinical evidence on how to effectively integrate wearable device data into these personalized strategies for specific patient populations. Moreover, the prognostic impact of wearable device-assisted remote management has not been comprehensively evaluated. Therefore, robust clinical studies are needed to further evaluate whether wearable device-assisted remote monitoring can improve the long-term prognosis of this population after discharge from the cardiac care unit (CCU).\n\nIn this study (WARM-HF Stage 2), the investigators will conduct a prospective, multicenter, randomized controlled trial to determine whether wearable devices can reduce the composite endpoint of readmission or death in patients with HF.",[168,169],"Atrial Fibrillation (AF)","Heart Failure and Reduced Ejection Fraction","2026-07-07",{"date":172,"type":34},"2026-07-09",{"date":174,"type":21},"2026-09-01",{"date":176,"type":21},"2028-12-30",{"name":40,"class":41},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":51,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":131},"100611998","balloon-guide-catheter-combined-with-filter-protection-for-carotid-artery-stenting-100611998","NCT07247864","Balloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting","A Comparative Study of Carotid Artery Stenosis Stenting With Balloon Guide Catheter Combined With Distal Filter Versus Distal Filter Alone-A Multicenter, Prospective, Open-label, Endpoint-blinded, Randomized Controlled Study","ANGEL-BEACON","1. Occlusion or severe stenosis (70% or greater) of the intracranial segment of the ipsilateral internal carotid artery system;\n2. Occlusion or severe stenosis (70% or greater) of the contralateral common carotid artery or internal carotid artery;\n3. History of stenting in the head and neck vessels within 3 months;\n4. Coexisting other cerebrovascular diseases, such as intracranial aneurysms greater than 5 mm or cerebrovascular malformations;\n5. Onset of stroke within 7 days;\n6. Large old infarctions from previous stroke that may confound the evaluation of endpoints;\n7. Contraindications to magnetic resonance imaging (MRI);\n8. Definite risk of cardiogenic embolism (e.g., atrial fibrillation, atrial flutter, intracardiac thrombus) or clear indications for anticoagulation therapy;\n9. Absolute or relative contraindications to antiplatelet therapy;\n10. Pregnant or lactating women;\n11. Allergy or hypersensitivity to contrast media or stent materials (e.g., Nitinol);\n12. Life expectancy less than 1 year;\n13. Pre-existing neurological or psychiatric disorders (e.g., severe dementia) that would confound neurological assessments;\n14. Severe renal insufficiency (eGFR less than 30 mL\u002Fmin).",{"count":187,"type":21},296,[53],"This multicenter, randomized, controlled trial evaluates a combined embolic protection strategy during carotid artery stenting (CAS). Carotid artery stenosis is a major cause of stroke. While stenting is an effective treatment, the procedure itself carries a risk of dislodging plaque debris, which can travel to the brain and cause new strokes or silent brain infarctions.\n\nCurrently, a distal filter (protection device) is standardly used to catch debris. However, it may not capture all particles. This study investigates whether adding a Balloon Guide Catheter (BGC)-which temporarily stops blood flow and allows for aspiration-to the standard filter protection is more effective than using the filter alone.\n\nPatients with symptomatic (≥50% stenosis) or asymptomatic (≥70% stenosis) carotid artery stenosis who are scheduled for stenting will be randomly assigned to one of two groups:\n\n1. Combined Protection Group: Receiving CAS using a Balloon Guide Catheter combined with a distal filter.\n2. Standard Protection Group: Receiving CAS using a distal filter alone. The primary goal is to determine if the combined approach reduces the number of new ischemic lesions detected on brain MRI within 72 hours post-procedure. The study will also assess clinical stroke events over a 90-day follow-up period.",[191],"Carotid Artery Stenosis",[193,194,195,196,197],"Carotid artery stenosis","Carotid Artery Stenting","Balloon Guide Catheter","Embolic Protection Device","New Ischemic Lesions","2026-07-02",{"date":200,"type":34},"2026-07-06",{"date":202,"type":34},"2025-12-03",{"date":204,"type":21},"2027-12-01",{"name":40,"class":41},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":51,"phases":217,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":228,"locationsCount":131},"100623986","wellbeing-and-survival-improvement-with-event-reduction-by-ablation-for-atrial-fibrillation-in-the-very-elderly-100623986","NCT07403760","Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly","Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (WISER-AF)","WISER-AF","Inclusion Criteria:\n\n1. Age ≥ 80 years.\n2. Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment.\n3. Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea).\n4. Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n1. NYHA Class IV heart failure.\n2. Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year.\n3. Long-standing persistent AF (duration \\> 1 year).\n4. Left atrial anteroposterior diameter \\> 6 cm.\n5. History of prior AF ablation.\n6. AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism).\n7. Severe mitral stenosis.\n8. Moderate to severe hepatic failure (Child-Pugh B-C).\n9. Renal failure stage 4-5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2) or continuous dialysis.\n10. Inability to cooperate due to dementia or severe mental disorder.\n11. Presence of left atrial thrombus.\n12. Prior Left Atrial Appendage Occlusion (LAAO).\n13. Contraindication to anticoagulation.\n14. Life expectancy \\\u003C 1 year.","80 Years",{"count":216,"type":21},136,[53],"The WISER-AF trial is a multicenter, double-blind, sham-controlled, randomized controlled trial. It aims to evaluate the efficacy and safety of catheter ablation compared to a sham procedure in improving the quality of life (SF-36 score) in very elderly patients (aged ≥80 years) with symptomatic atrial fibrillation over a 6-month follow-up period.",[168],[221,222,223],"catheter ablation","very elderly","quality of life","2026-07-01",{"date":200,"type":34},{"date":224,"type":21},{"date":176,"type":21},{"name":40,"class":41},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":51,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":131},"100632789","comparison-of-femorofemoral-bypass-and-left-heart-bypass-techniques-in-open-thoracoabdominal-aortic-aneurysm-repair-100632789","NCT07518251","CompaRison of FEmorofemoral Bypass and Left-Heart ByPass Techniques in Open Thoracoabdominal AortIc Aneurysm Repair","Comparison of Femorofemoral Bypass and Left-Heart Bypass Techniques in Open Thoracoabdominal Aortic Aneurysm Repair: A Study Protocol for Multicenter, Two-Arm, Open-Label, Randomized, ParalleI-Controlled Non-Inferiority Trial","REPAIR","Inclusion Criteria:\n\n1. Computed tomography angiography (CTA) confirmed as ATAAD according to the 2022 ACC\u002FAHA Guideline for the Diagnosis and Management of Aortic Disease;\n2. Adult patients (≥18 years old);\n3. Indications for TAAAR are available and requiring cardiopulmonary bypass;\n4. Signed informed consent and availability for follow-up.\n\nExclusion Criteria:\n\n1. History of chronic renal failure, chronic heart failure, Coronary heart disease with established surgical indications, hepatocirrhosis, and hepatic insufficiency;\n2. History of severe cerebral infarction (with cerebral infarction sequels);\n3. Inflammatory aortic diseases, such as Takayasu arteritis and Behçet's disease, etc;\n4. History of infectious aortic diseases;\n5. History of malignancy or previous radiotherapy;\n6. Pregnant or feeding women, or anyone planning to reproduce during the test period;\n7. Participating in any other clinical trial;\n8. Having other causes not eligible for operation.",{"count":238,"type":21},236,[53],"The study is a multicenter, two-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 236 participants diagnosed with TAAA from 4 hospitals in China. All patients receive TAAAR procedure and are randomized to control group (LHB) and experimental group (fCPB) in the ratio of 1:1. After a 1-year follow-up, the validity and safety of the different cardiopulmonary bypass for TAAAR is evaluated via the incidence of major adverse events including surgical mortality, RRT, stroke, and SCI, as well as intraoperative blood product transfusion volume, mechanical ventilation, and early mortality.",[242,243,244],"Thoracoabdominal Aortic Aneurysm","Cardiopulmonary Bypass","Open Repair","2026-06-30",{"date":224,"type":34},{"date":248,"type":34},"2026-03-06",{"date":250,"type":21},"2028-08",{"name":40,"class":41},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":51,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":4},"100624556","wearable-device-assisted-remote-management-in-atrial-fibrillation-complicated-by-heart-failure-warm-hf-trial-100624556","NCT07411170","Wearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial","Wearable Device-assisted Remote Management for Patients With Atrial Fibrillation Complicated by Heart Failure: A Prospective, Open-label, Multi-center, Randomized Controlled Trial","WARM-HF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Subjects diagnosed with acute decompensated heart failure (ADHF) :1)Heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40%;2)New York Heart Association (NYHA) functional class II-IV;3)NT-proBNP \\> 2500 pg\u002FmL or BNP \\> 600 pg\u002FmL\n3. Atrial fibrillation (AF) diagnosed during hospitalization (documented AF episode lasting \\> 30 seconds on electrocardiogram \\[ECG\\] within the past 12 months)\n\nExclusion Criteria:\n\n1. Intolerance to heart failure pharmacotherapy\n2. Severe anemia, uncorrected thyroid disease\n3. ST-segment elevation myocardial infarction (STEMI) within 3 months\n4. Known complex congenital\u002Fsecondary heart disease; infiltrative cardiomyopathy (e.g., cardiac amyloidosis, sarcoidosis, lymphoma, or endomyocardial fibrosis); myocarditis; constrictive pericarditis; cardiac tamponade; hypertrophic cardiomyopathy; stress cardiomyopathy (Takotsubo cardiomyopathy); or uncorrected primary valvular heart disease requiring surgical intervention.\n5. Previous or planned major cardiac surgery or mechanical circulatory support within 6 months, including coronary artery bypass grafting, cardiac valve repair or replacement, ventricular assist device or mechanical circulatory support device implantation, and heart transplantation.\n6. Current use of or planned implantation of a pacemaker.\n7. Contraindications to wearing a smartwatch (e.g., limb disability or known allergy to rubber\u002Fmetal materials)\n8. Inability to access the Internet or lack of proficiency in operating smart devices\n9. Pregnant or lactating women\n10. Organ transplantation within the past 12 months\n11. Expected survival time of less than 1 year for any reason\n12. Refusal to participate or inability to comply with follow-up requirements\n13. Deemed ineligible for participation in the study by the investigators",{"count":261,"type":21},400,[53],"Patients with acute decompensated heart failure (HF) have a significantly high risk of death and HF re-hospitalization during the vulnerable phase post discharge. Therefore, early post-discharge management is crucial, and the cornerstone of HF treatment-particularly for HF with reduced ejection fraction (HFrEF)-is guideline-directed medical therapy (GDMT), a comprehensive pharmacotherapeutic strategy supported by robust clinical evidence. Timely titration of GDMT, especially within the first few weeks after discharge, has been shown to improve clinical outcomes, reduce readmissions, and enhance long-term prognosis. However, ensuring optimal follow-up and therapeutic adjustments remains a major challenge in real-world practice. Atrial fibrillation (AF) is a common comorbidity in patients with HF, especially in those with severe HF. The presence of AF significantly complicates the clinical course and worsens the prognosis of HF.\n\nAdvances in wearable technology have made continuous, non-invasive monitoring of vital signs, arrhythmia burden, and physical status increasingly feasible. Devices such as smartwatches and ECG belts can provide real-time physiological data, offering new opportunities for remote and proactive disease management. Despite the growing availability of such data, the complex interplay between AF and HF demands highly personalized management. Currently, there is a lack of high-quality clinical evidence on how to effectively integrate wearable device data into personalized strategies for this specific patient population.\n\nThis is an open-label, multi-center, endpoint-blinded, parallel-group randomized clinical trial supported by the American Heart Association. The primary objective is to determine whether wearable device-assisted digital consultations can optimize GDMT in patients with AF complicated by acute decompensated HF. The study plans to enroll 400 participants, who will be randomly assigned to either a wearable device-assisted intervention group or a conventional treatment control group. The primary endpoint is the change in HF GDMT score 3 months after randomization.\n\nApple Inc. provided funding, devices, and technical support for this study. Apple was not a sponsor of the trial and was not involved in its execution, data analysis, interpretation, or manuscript preparation.",[265,99],"HFrEF - Heart Failure With Reduced Ejection Fraction","2026-06-25",{"date":268,"type":34},"2026-06-29",{"date":270,"type":21},"2026-08",{"date":272,"type":21},"2028-09",{"name":40,"class":41},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":51,"phases":285,"briefSummary":286,"conditions":287,"keywords":293,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":307},"100627110","start-cpap-therapy-in-obstructive-sleep-apnea-patients-after-atrial-fibrillation-ablation-100627110","NCT07444372","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial","STOP-AFib","Inclusion Criteria:\n\nPatients must meet all of the following conditions to be eligible for the study:\n\n* Age 18-75 years.\n* Patients with persistent AF scheduled for first-time catheter ablation.\n* Diagnosed with OSA.\n* Able to tolerate CPAP therapy.\n* Capable of understanding and complying with the study protocol.\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n* Secondary AF.\n* Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).\n* Left ventricular ejection fraction \\\u003C 30%.\n* Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).\n* Pregnant or breastfeeding women.\n* History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.\n* History of stroke or transient ischemic attack within 6 months prior to screening.\n* Perioperative complications related to the ablation procedure occurring prior to randomization.\n* Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.\n* Life expectancy \\\u003C 1 year.\n* Central sleep apnea.\n* Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI \\> 30kg\u002Fm² and awake PaCO₂ \\> 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with \\> 1 episode of respiratory failure or hypercapnia.\n* Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.\n* Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.\n* Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.\n* Current participation in other drug or device trials.","75 Years",{"count":284,"type":21},658,[53],"Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.\n\nThis study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.\n\nParticipants will:\n\n* Be randomly assigned to either the CPAP group or the usual care group.\n* If in the CPAP group, use a CPAP device for 12 months.\n* Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months post-operation.\n* Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after their procedure.",[288,289,168,290,291,292],"Obstructive Sleep Apnea","Sleep Disorder (Disorder)","Sleep Disordered Breathing (SDB)","Arrhythmia","Continuous Positive Airway Pressure",[288,292,294,295,296,297,298],"Atrial Fibrillation","Ablation of atrial fibrillation","Sleep Disordered Breathing","Clinical Trial","Catheter Ablation","2026-06-14",{"date":301,"type":34},"2026-06-16",{"date":303,"type":34},"2026-05-12",{"date":305,"type":21},"2029-01-31",{"name":40,"class":41},27,{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":131},"100643371","cohort-study-of-postoperative-cognitive-dysfunction-after-off-pump-coronary-artery-bypass-grafting-100643371","NCT07643194","Cohort Study of Postoperative Cognitive Dysfunction After Off-Pump Coronary Artery Bypass Grafting","Risk of Postoperative Cognitive Dysfunction After Off-Pump Coronary Artery Bypass Grafting: A Prospective Cohort Study","OPCAB-POCD","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled to undergo elective off-pump coronary artery bypass grafting\n* American Society of Anesthesiologists physical status classification I to IV\n* Able to complete preoperative cognitive assessments, including the Mini-Mental State Examination and the Montreal Cognitive Assessment\n* Written informed consent provided by the patient or family member\n\nExclusion Criteria:\n\n* Emergency surgery\n* Pre-existing diagnosed cognitive impairment or history of psychiatric disease\n* Preoperative cognitive impairment\n* Severe neurological disease, such as sequelae of stroke, that may interfere with cognitive assessment\n* Severe visual or hearing impairment that prevents completion of cognitive assessment\n* Inability to understand Chinese or presence of language communication barriers",{"count":317,"type":21},600,"This prospective cohort study aims to investigate postoperative cognitive dysfunction in patients undergoing off-pump coronary artery bypass grafting. Eligible patients will be enrolled before surgery and followed after surgery. Cognitive function will be assessed using the Montreal Cognitive Assessment before surgery and at predefined postoperative time points. Perioperative clinical information, including preoperative assessment data, intraoperative monitoring parameters, and postoperative clinical data, will be collected. The study will evaluate the occurrence of postoperative cognitive dysfunction and explore its association with perioperative factors.",[320],"Postoperative Cognitive Dysfunction (POCD)",[322,323,324,325,326],"Postoperative Cognitive Dysfunction","Off-Pump Coronary Artery Bypass Grafting","OPCABG","Montreal Cognitive Assessment","Prospective Cohort Study","2026-06-09",{"date":329,"type":34},"2026-06-11",{"date":331,"type":21},"2026-05-24",{"date":333,"type":21},"2026-12-15",{"name":40,"class":41},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":51,"phases":345,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100641036","phase-2-all-trans-retinoic-acid-for-the-treatment-of-hemophagocytic-lymphohistiocytosis-100641036","NCT07626398","All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis","An Open-Label Study Evaluating the Safety and Efficacy of All-Trans Retinoic Acid in Patients With Hemophagocytic Lymphohistiocytosis","* Inclusion Criteria\n\n  1. Age ≥18 years.\n  2. Patients diagnosed with active hemophagocytic lymphohistiocytosis according to HLH-2004 diagnostic criteria or the investigator's clinical assessment.\n  3. Newly diagnosed or treatment-naïve active HLH requiring initial HLH-directed therapy.\n  4. Presence of active disease manifestations, including at least one of the following: persistent fever, cytopenia, hyperferritinemia, splenomegaly, hypofibrinogenemia and\u002For hypertriglyceridemia, elevated soluble CD25, hemophagocytosis, reduced or absent NK-cell activity, or other HLH-related organ involvement.\n  5. Eastern Cooperative Oncology Group performance status of 0-3, or performance status considered acceptable by the investigator in the context of active HLH.\n  6. Adequate ability to receive oral medication, or ability to receive ATRA through an appropriate enteral route.\n  7. Expected survival of more than 48 hours in the judgment of the investigator.\n  8. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use effective contraception during treatment and for an appropriate period after the last dose of ATRA.\n  9. Ability to understand and willingness to sign written informed consent. For patients unable to provide consent because of disease severity, consent may be provided by a legally authorized representative according to local regulations.\n* Exclusion Criteria\n\n  1. Prior systemic HLH-directed therapy for the current HLH episode, including etoposide-based therapy, ruxolitinib, emapalumab, alemtuzumab, PD-1 blockade, or other investigational HLH-directed treatment. Short-term corticosteroids, supportive care, anti-infective therapy, or emergency treatment before enrollment may be allowed at the investigator's discretion.\n  2. Known hypersensitivity to all-trans retinoic acid, tretinoin, retinoids, or any component of the study drug.\n  3. Pregnant or breastfeeding women.\n  4. Patients with acute promyelocytic leukemia or other diseases for which ATRA is being used as standard leukemia-directed therapy.\n  5. Severe uncontrolled infection, shock, respiratory failure, bleeding, or organ failure that, in the investigator's judgment, would make participation unsafe or prevent assessment of study treatment.\n  6. Severe hepatic dysfunction not primarily attributed to HLH, such as total bilirubin or transaminase levels considered unsafe for ATRA administration by the investigator.\n  7. Severe renal dysfunction requiring dialysis before enrollment, unless considered related to HLH and acceptable by the investigator.\n  8. Active intracranial hypertension, pseudotumor cerebri, or uncontrolled severe neurologic disease that may increase the risk of ATRA-related toxicity.\n  9. Uncontrolled hypertriglyceridemia or other metabolic abnormality that, in the investigator's judgment, would make ATRA treatment unsafe.\n  10. Concomitant use of vitamin A supplements, other systemic retinoids, or medications with unacceptable interaction risk that cannot be discontinued.\n  11. Any other condition that, in the investigator's judgment, would interfere with patient safety, protocol compliance, or interpretation of study results.","65 Years",{"count":344,"type":21},30,[76,346],"PHASE3","This study is designed to evaluate the safety and preliminary efficacy of all-trans retinoic acid (ATRA) as an initial treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). HLH is a severe hyperinflammatory syndrome caused by excessive activation of immune cells and uncontrolled cytokine release. Current treatment often requires intensive immunosuppressive or cytotoxic therapy, which may be associated with significant toxicity.\n\nATRA is an orally available agent that has been widely used in other hematologic diseases and has immunomodulatory effects. Preclinical studies suggest that ATRA may help control HLH-related inflammation and improve immune dysregulation. In this study, patients with newly diagnosed or treatment-naïve active HLH will receive ATRA-based initial therapy. The study will assess clinical response, changes in HLH-related inflammatory markers, organ function, viral or disease-related parameters when applicable, and treatment-related adverse events.\n\nThe goal of this study is to determine whether ATRA can provide a safe and feasible initial therapeutic approach for active HLH and support further clinical development of ATRA-based treatment strategies in this disease.",[349],"Hemophagocytic Lymphohistiocytosis (HLH)","2026-06-02",{"date":352,"type":34},"2026-06-04",{"date":354,"type":21},"2026-06-01",{"date":356,"type":21},"2029-06-01",{"name":40,"class":41},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":366,"targetDuration":368,"studyType":23,"phases":4,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":382},"100594859","complex-arrhythmia-registry-100594859","NCT07024927","Complex Arrhythmia Registry","Complex Arrhythmia Registry（CAR）： Long-term Outcomes of Catheter Ablation for Atrial Fibrillation or Ventricular Tachycardia： A Multicenter， Prospective Cohort Study","CAR","1. Atrial Fibrillation (AF) Cohort:\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).\n     3. Scheduled to undergo first-time catheter ablation for AF.\n     4. Procedure to be performed using a 3D mapping system.\n     5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).\n     2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).\n     3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment\u002Fprocedure.\n     4. Severe active infection (e.g., septic shock, sepsis).\n     5. Contraindications to anticoagulation therapy.\n     6. Current participation in another interventional clinical trial that may confound the results of this study.\n     7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.\n2. Ventricular Tachycardia (VT) Cohort\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:\n     3. Ischemic heart disease (e.g., prior MI, coronary artery disease).\n     4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).\n     5. Scheduled to undergo first-time catheter ablation for VT.\n     6. Procedure to be performed using a 3D mapping system.\n     7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).\n     2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).\n     3. Cardiac surgery within 60 days prior to the planned ablation procedure.\n     4. Severe coagulopathy (e.g., platelet count \\\u003C 50 x 10⁹\u002FL, disseminated intravascular coagulation (DIC)).\n     5. Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 20%.\n     6. Severe active infection (e.g., septic shock, sepsis).\n     7. Current participation in another interventional clinical trial that may confound the results of this study.\n     8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.",{"count":367,"type":21},4000,"3 Years","This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.",[168,121],[372,373,374,375],"atrial fibrillation","ventricular tachycardia","ablation","registry study",{"date":352,"type":34},{"date":378,"type":34},"2025-10-21",{"date":380,"type":21},"2032-06",{"name":40,"class":41},2,{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":390,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":402,"leadSponsor":403,"locationsCount":4},"100637999","correlation-and-prognostic-value-of-body-composition-cardiac-structure-and-function-in-patients-with-different-heart-failure-subtypes-100637999","NCT07619222","Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Heart Failure Subtypes","Study on the Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Subtypes of Heart Failure","Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for heart failure set forth in the 2022 ESC Guidelines: presence of typical symptoms (e.g., dyspnea, fatigue, edema, etc.) and signs (e.g., pulmonary rales, jugular venous distention, third heart sound, etc.) of heart failure;\n2. Undergoing both coronary computed tomography angiography (CCTA) and non-contrast chest computed tomography (CT), with image quality meeting the requirements for quantitative analysis;\n3. Age ≥ 18 years, with complete clinical and follow-up data, and ability to cooperate with imaging examinations and follow-up assessments.\n\nExclusion Criteria:\n\n1. Acute myocardial infarction occurring within 3 months prior to the imaging examination;\n2. Other definite structural heart diseases, including congenital heart disease, myocarditis, pericardial disease, severe valvular heart disease, etc.;\n3. End-stage organ diseases (hepatic\u002Frenal\u002Fpulmonary failure, active malignancy);\n4. Unmeasurable scan images (e.g., due to pericardial effusion or artifacts);\n5. Incomplete or missing clinical data.",true,{"count":117,"type":21},"Heart failure (HF) refers to impaired cardiac function caused by various heart diseases. Patients commonly present with dyspnea, fatigue, edema and other symptoms, ranking among the leading causes of death from cardiovascular diseases worldwide. According to World Health Organization statistics, more than 26 million people globally suffer from heart failure. The rising prevalence of aging population, hypertension, diabetes and other comorbidities continues to expand the patient population, imposing a heavy burden on families and society.\n\nBody mass index (BMI) was traditionally adopted to assess the correlation between obesity and heart failure, yet this method has inherent limitations. The obesity paradox indicates that obese heart failure patients may achieve better recovery outcomes than those with normal weight. Additionally, BMI fails to differentiate the impacts of adipose tissues distributed in distinct anatomical sites. Advances in imaging technology have enabled accurate quantification of regional fat deposits, including epicardial adipose tissue (EAT), subcutaneous adipose tissue (SAT) and intramuscular adipose tissue (IMAT).\n\nDomestic and international studies have verified that fat distribution exerts greater influence than total fat volume. Directly adjacent to the myocardium, EAT may secrete inflammatory mediators and induce myocardial injury. SAT produces protective bioactive substances, while its effects vary across heart failure subtypes and remain inconclusive. IMAT is correlated with reduced physical activity and poor clinical prognosis. Nevertheless, most existing researches focus solely on single-site fat tissue or specific heart failure types. Comprehensive combined analysis of cardiac, somatic and muscular adipose tissues, as well as systematic comparison among diverse heart failure subtypes, remains insufficient.\n\nThis study intends to quantify the three types of adipose tissues simultaneously, combined with cardiac structural and functional examinations, to explore their associations with heart failure. The findings are expected to facilitate precise risk stratification and individualized therapeutic strategy formulation for clinicians.",[394],"Heart Failure",[396,397,398],"heart failure","body composition","cardiac MRI",{"date":400,"type":34},"2026-06-03",{"date":354,"type":21},{"date":86,"type":21},{"name":40,"class":41},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":390,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":131},"100640338","prospective-study-on-the-effectiveness-and-safety-of-bi-polar-pulse-field-tip-catheter-ablation-for-atrial-fibrillation-in-chinapotential-af-100640338","NCT07627685","Prospective Study on the Effectiveness and Safety of Bi-polar Pulse-field Tip-catheter Ablation for Atrial Fibrillation in China（POTENTIAL-AF）","POTENTIAL-AF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Symptomatic paroxysmal AF or persistent AF:\n\n   * Paroxysmal AF: self-terminating within ≤ 7 days; ≥ 2 symptomatic episodes in the 6 months prior to enrolment; ≥ 1 ECG or Holter-documented AF episode in the 12 months prior to enrolment\n   * Persistent AF: duration \\> 7 days and \\\u003C 1 year; ≥ 1 symptomatic episode in the 6 months prior; documented by Holter or 2 ECGs ≥ 7 days apart within 12 months prior\n3. Failure of AAD therapy: inadequate efficacy and\u002For intolerance to ≥ 1 Class I or Class III antiarrhythmic drug\n4. Planned PFA catheter ablation for AF\n5. Voluntary participation with written informed consent Willing and able to comply with study procedures and follow-up (including in-hospital assessment, 30-day and 90-day follow-up)\n\nExclusion Criteria:\n\n1. AF attributable to a reversible cause (e.g., hyperthyroidism, peri-operative or cardiac\u002Fthoracic surgery-related AF)\n2. Concomitant condition with expected survival \\\u003C 1 year (e.g., advanced malignancy)",{"count":412,"type":21},30000,"POTENTIAL-AF is a prospective, multicentre, observational registry study evaluating the real-world effectiveness and safety of bi-polar pulse-field tip-catheter ablation (PFA) for atrial fibrillation (AF) in China. The study will enrol 30,000 adult patients with symptomatic paroxysmal or persistent AF who have failed at least one antiarrhythmic drug (Class I or III) and are planned to undergo PFA using the Jinjiang LEAD-PFA system with PulsedFA catheter at participating centres across China.\n\nAll procedural decisions, including energy settings, ablation targets, and peri-procedural management, are made by the treating physician per routine clinical practice. The study prospectively collects baseline clinical characteristics, intraoperative ablation parameters, and follow-up outcomes at 3 months, 6 months, 12 months, and every 6 months thereafter, for up to 10 years.\n\nThe primary endpoint is all-cause mortality at 10 years. Secondary endpoints (observed over 5 years) include ischaemic stroke, haemorrhagic stroke, transient ischaemic attack (TIA), cardiovascular death, cardiovascular hospitalisation, systemic embolism, thromboembolic death, major bleeding, and clinically relevant non-major bleeding (CRNMB).\n\nBy capturing large-scale, standardised, long-term data across diverse Chinese centres, POTENTIAL-AF aims to describe real-world procedural practice patterns, identify predictors of clinical outcomes, and provide evidence to support the safe and effective application of the Jinjiang bi-polar tip PFA catheter in Chinese AF patients.",[294],[416,298,417],"Pulsed Field Ablation","Pulmonary Vein Isolation","2026-05-31",{"date":352,"type":34},{"date":174,"type":21},{"date":422,"type":21},"2036-09-30",{"name":40,"class":41},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":390,"sex":17,"minAge":431,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":51,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":441,"locationsCount":4},"100639905","effectiveness-of-patch-electrocardiogram-recorders-in-screening-for-atrial-fibrillation-in-elderly-people-in-the-chinese-community-100639905","NCT07627672","Effectiveness of Patch-Electrocardiogram Recorders in Screening for Atrial Fibrillation in Elderly People in the Chinese Community","Effectiveness of Patch-Electrocardiogram Recorders in Screening for Atrial Fibrillation in Elderly People in the Chinese Community: A Prospective Multicenter Study","Inclusion Criteria:\n\n* Age ≥60 years\n* No prior diagnosis of atrial fibrillation\n* Able to understand the study purpose and willing to provide written informed consent\n* No severe cardiac disease, acute illness, or contraindication to ECG monitoring\n* Able to wear the patch ECG device and comply with continuous monitoring requirements\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to cooperate with follow-up assessments\n* Pregnant or breastfeeding women\n* Previously diagnosed with atrial fibrillation and already receiving treatment","60 Years",{"count":412,"type":21},[53],"This prospective, multicenter, single-arm study evaluates the effectiveness of a single-lead patch electrocardiogram (ECG) recorder in screening for atrial fibrillation (AF) among community-dwelling elderly individuals aged ≥60 years in China. Participants will undergo 7 days of continuous ECG monitoring, followed by annual follow-up for up to 10 years to assess long-term outcomes including stroke, heart failure, and death.",[294],[437],"Atrial fibrillation; AF screening; Patch ECG; Wearable ECG; Elderly; Community screening; China; FINDING-AF",{"date":352,"type":34},{"date":174,"type":21},{"date":422,"type":21},{"name":40,"class":41},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":342,"enrollmentInfo":449,"targetDuration":4,"studyType":51,"phases":451,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":463},"100640759","phase-4-effect-of-the-traditional-chinese-medicine-yufeng-ningxin-in-patients-with-hypertension-100640759","NCT07607275","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Male and female participants aged 18-65 years;\n2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;\n3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent.\n\nExclusion Criteria:\n\n1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);\n2. Orthostatic hypotension (symptomatic or asymptomatic);\n3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;\n4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);\n5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;\n6. Severe hepatic or renal diseases (ALT \\>3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2);\n7. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c\\>9.0%);\n8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \\[TIA\\]);\n9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;\n10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;\n11. NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;\n12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;\n13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;\n14. Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS);\n15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent;\n16. Participants preparing for or under pregnancy and\u002For lactation;\n17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);\n18. Other conditions deemed inappropriate for participation by the investigators.",{"count":450,"type":21},350,[452],"PHASE4","Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials. Here, the investigators conducted a double-blind, randomized controlled trial to assess the efficacy and safety of Yufeng Ningxin tablets in patients with hypertension.",[455,456],"Hypertension","Essential (Primary) Hypertension","2026-05-29",{"date":350,"type":34},{"date":460,"type":21},"2026-05-15",{"date":86,"type":21},{"name":40,"class":41},16,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":471,"targetDuration":4,"studyType":51,"phases":473,"briefSummary":474,"conditions":475,"keywords":480,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":4},"100637367","phase-2-effect-of-guanxinning-tablet-on-coronary-microcirculation-after-primary-percutaneous-coronary-intervention-in-patients-with-acute-myocardial-infarction-100637367","NCT07621107","Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","A Randomized Explorative Pre-trial of the Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Age between 18 and 80 years (gender is not restricted).\n* STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019\" and the fourth - edition \"Global Definition of Myocardial Infarction\" criteria, myocardial infarction refers to acute myocardial injury \\[serum cardiac troponin (cTn) increases and\u002For decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.)\n* Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \\\u003C 20% after stent implantation or \\\u003C 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2).\n* Signed a written informed consent form.\n\nExclusion Criteria:\n\n* Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia.\n* LVEF \\\u003C 40%.\n* Currently using nicorandil, other Chinese patent medicines, and Chinese herbal decoctions, etc.\n* Unable to undergo CMR examination for various reasons.\n* Expected to be unable to complete 6 - month treatment with Guanxinning Tablets.\n* Contraindications or allergies to Guanxinning Tablets.\n* Suspected or confirmed hereditary cardiomyopathy (such as hypertrophic, dilated, obstructive cardiomyopathy, cardiac amyloidosis, hemochromatosis cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, etc.).\n* Active or chronic liver disease.\n* Renal insufficiency (eGFR \\\u003C 60ml\u002Fmin\u002F1.73m²).\n* History of previous cerebral hemorrhage.\n* History of alcohol or drug abuse.\n* Known active infection, or severe hematological, metabolic, or endocrine dysfunction.\n* Patients who have received systemic steroid or cyclosporine treatment in the past 3 months.\n* Active malignant tumor.\n* Life expectancy less than 6 months.\n* Pregnant or lactating women.\n* Already participating in other clinical studies.",{"count":472,"type":21},70,[76],"①Research objective: In a small sample population, through the pre - experimental method, explore and evaluate the effect of Guanxinning tablets on the coronary microcirculation after primary percutaneous coronary intervention (PPCI) in patients with acute ST - segment elevation myocardial infarction (STEMI), with the change in the percentage of intramyocardial hemorrhage (IMH) in ventricular mass measured by cardiac magnetic resonance (CMR) imaging as the primary endpoint.\n\n②Research significance: The research results of this project will provide preliminary theoretical basis and methodological support for the formal randomized controlled study on evaluating the effect of Guanxinning tablets on the coronary microcirculation after PPCI in STEMI patients. It will offer new ideas for the long - term clinical treatment of STEMI patients after PPCI, and provide important theoretical support for expanding the clinical indications of Guanxinning tablets and exploring the reasons for its improvement of cardiovascular outcomes.",[476,477,478,479,26],"STEMI (ST Elevation MI)","STEMI - ST Elevation Myocardial Infarction","STEMI","CMD",[481,482,483,484,485],"TCM","traditional chinese medicine","guanxinning tablet","CMR","intramyocardial hemorrhage","2026-05-27",{"date":350,"type":34},{"date":354,"type":21},{"date":490,"type":21},"2027-02-01",{"name":40,"class":41},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":500,"targetDuration":4,"studyType":51,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":511,"leadSponsor":513,"locationsCount":131},"100640955","target-oriented-strategy-of-ultra-low-ldl-c-10-vs-10-139-mmoll-in-extreme-high-risk-ascvd-patients-clinical-benefit-safety-and-cost-effectiveness-assessment-100640955","NCT07615296","Target-Oriented Strategy of Ultra-Low LDL-C (\u003C1.0 vs. 1.0-1.39 mmol\u002FL) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment","Target-Oriented Strategy of Ultra-Low LDL-C Goal in Extreme-High-Risk ASCVD Patients (\u003C1.0 vs. 1.0-1.39 mmol\u002FL): Clinical Benefit, Safety and Cost-Effectiveness Assessment- A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint Adaptive Trial","TARGET-EXTREME","Inclusion Criteria:\n\n1. Aged 18-80 years, any sex.\n2. Diagnosed with ultra-high-risk ASCVD per 2023 Chinese Lipid Guidelines: either ≥2 major ASCVD events within 24 months, or 1 major ASCVD event plus ≥2 high-risk factors (diabetes, multi-vessel disease, premature CHD family history, elevated Lp(a), hypertension).\n3. LDL-C ≥1.0 mmol\u002FL after ≥4-week maximum-tolerated statin plus ezetimibe therapy, confirmed by central laboratory.\n4. Able to complete follow-up and examinations; no severe hepatic\u002Frenal dysfunction.\n5. Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity or intolerance to statins, ezetimibe, or PCSK9 inhibitors.\n2. Hemorrhagic stroke, active bleeding, severe trauma or major surgery within 6 months before enrollment.\n3. Malignancy (expected survival \\\u003C3 years), severe liver\u002Fkidney disease, or autoimmune disease.\n4. Cognitive impairment (MoCA \\\u003C20) or psychiatric disorders precluding assessment cooperation.\n5. Pregnant, breastfeeding, or planning pregnancy during the trial.\n6. Participation in other clinical trials or use of other lipid-lowering drugs within 3 months.\n7. Poor compliance or other conditions judged by investigators to interfere with the study.",{"count":501,"type":21},6000,[53],"The goal of this clinical trial is to learn whether an ultra-low LDL-C target (\\\u003C1.0 mmol\u002FL) can improve clinical outcomes compared with a moderately low LDL-C target (1.0-1.39 mmol\u002FL) in Chinese patients with extreme-high-risk atherosclerotic cardiovascular disease (ASCVD). It also aims to evaluate long-term safety and cost-effectiveness, and explore potential benefit subgroups and underlying mechanisms. The main questions it aims to answer are:\n\nDoes an LDL-C target \\\u003C1.0 mmol\u002FL reduce major adverse cardiovascular events (MACE-4: cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, urgent coronary revascularization) compared with a target of 1.0-1.39 mmol\u002FL?What are the long-term safety risks including cognitive decline, hemorrhagic stroke, new-onset diabetes, new malignancies and severe adverse drug reactions under different LDL-C targets?Researchers will compare participants receiving an LDL-C target \\\u003C1.0 mmol\u002FL with those receiving a target of 1.0-1.39 mmol\u002FL to see if the ultra-low LDL-C strategy provides better clinical benefit with acceptable safety and economic value.\n\nParticipants will:\n\nReceive lipid-lowering therapy following a mandatory titration-maintenance-off-target correction algorithm according to their assigned LDL-C target Undergo routine follow-up every 3 months, cognitive assessment every 6 months, and comprehensive annual re-examinations for a median of 2 years and up to 5 years Have centralized blinded lipid testing and endpoint adjudication by an independent Clinical Event Committee",[505],"Atherosclerotic Cardiovascular Disease (ASCVD)",[507],"Extreme-high-risk ASCVD, LDL-C target, Ultra-low LDL-C, Lipid-lowering therapy","2026-05-23",{"date":457,"type":34},{"date":36,"type":21},{"date":512,"type":21},"2031-12-31",{"name":40,"class":41},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":521,"targetDuration":118,"studyType":23,"phases":4,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":131},"100638048","active-post-market-surveillance-of-innovative-devices-for-valvular-heart-disease-100638048","NCT07605624","Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease","An Active Post-Market Surveillance Study Assessing the Real-World Clinical Applicability, Long-Term Safety, and Effectiveness of Innovative Medical Devices for Valvular Heart Disease","Inclusion Criteria:\n\n* Patients with valvular heart disease (VHD) receiving treatment with prosthetic aortic valve replacement systems (transcatheter and surgical valves), transcatheter mitral valve edge-to-edge repair (TEER) systems, or transcatheter tricuspid valve annuloplasty systems\n* Age ≥ 18 years\n* Patients who voluntarily participate in the study and sign the informed consent form\n* Willing and able to comply with follow-up requirements",{"count":522,"type":21},5500,"This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.",[525,526,527,528],"Aortic Stenosis","Aortic Regurgitation","Mitral Regurgitation","Tricuspid Regurgitation","2026-05-18",{"date":531,"type":34},"2026-05-26",{"date":533,"type":21},"2026-05-10",{"date":305,"type":21},{"name":40,"class":41},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":390,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":51,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":559},"100621600","smartwatch-based-intervention-for-cardiovascular-health-switch-100621600","NCT07372729","Smartwatch-based Intervention for Cardiovascular Health (SWITCH)","A Smart Wearable Devices-based Comprehensive Intervention Through a Cluster Randomized Controlled Trial to Improve Cardiovascular Health in Overweight\u002FObese Individuals With Cardiometabolic Preconditions","Inclusion Criteria:\n\n1. Age \\>= 18 years, no gender restriction;\n2. Overweight and obesity: Body Mass Index (BMI) 24.0-32.4 kg\u002Fm\\^2, or waist circumference \\>= 90 cm for males and \\>= 85 cm for females;\n3. Presence of at least one metabolic high-risk state among prehypertension, prediabetes, or borderline elevated blood lipids, and without a diagnosis of hypertension, diabetes mellitus, or dyslipidemia:\n\n(1) Prehypertension: Systolic blood pressure (SBP) 130-139 mmHg and\u002For diastolic blood pressure (DBP) 80-89 mmHg, without regular use of antihypertensive medication in the past month; (2) Prediabetes: Fasting blood glucose (FBG) 6.1-6.9 mmol\u002FL, or glycated hemoglobin (HbA1c) 5.7%-6.4%, without regular use of hypoglycemic medication in the past month; (3) Borderline elevated blood lipids: Total cholesterol (TC) 5.2-6.1 mmol\u002FL, or low-density lipoprotein cholesterol (LDL-C) 3.4-4.0 mmol\u002FL, or triglycerides (TG) 1.7-2.2 mmol\u002FL, or non-high-density lipoprotein cholesterol (non-HDL-C) 4.1-4.8 mmol\u002FL, without regular use of lipid-lowering medication in the past month; 4. Local permanent residents who will reside in the area for at least 12 month after enrollment; 5. Have basic reading, writing, and comprehension abilities; proficient in using internet-connected smartphones; able to independently complete basic operations of the application; 6. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Secondary obesity diagnosed by doctors in secondary or higher-level medical institutions;\n2. Cardiovascular and cerebrovascular diseases, including myocardial infarction, stroke, heart failure, arrhythmia; or having received coronary intervention therapy, cardiac surgery, etc.; or with a 10-year high risk of cardiovascular disease;\n3. Diseases seriously affecting survival, such as malignant tumors, AIDS, hepatic and renal failure;\n4. Pregnancy, lactation period, or women who may become pregnant within one year;\n5. History of severe neuropsychiatric diseases with potential cognitive or communication impairments, such as dementia, Alzheimer's disease, Parkinson's syndrome;\n6. Individuals with limited daily mobility;\n7. Individuals undergoing or planning to receive weight loss through surgery, medication, or other methods;\n8. Currently participating in other lifestyle intervention-related trials.",{"count":544,"type":21},1400,[53],"This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among Overweight\u002FObese Individuals with Cardiometabolic Preconditions, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.",[548,549,550,551],"Prehypertension","Borderline Dyslipidemia","Overweight , Obesity","Prediabetes",{"date":553,"type":34},"2026-05-14",{"date":555,"type":34},"2026-03-24",{"date":557,"type":21},"2027-03-15",{"name":40,"class":41},3,{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":51,"phases":570,"briefSummary":571,"conditions":572,"keywords":575,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":131},"100537175","standby-cannulated-ecmo-for-high-risk-percutaneous-coronary-intervention-100537175","NCT06274411","Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention","Standby Cannulated ECMO Versus Prophylactic ECMO In Patients Undergoing High-Risk Percutaneous Coronary Intervention","ECMO-READY","Inclusion Criteria:\n\n1. Clinicians decide to perform PCI during ECMO support.\n2. Age of ≥18\n3. Patient presents with a compromised ejection fraction of less than 35% or at risk of hemodynamic deterioration, or intervention on the last patent coronary conduit or an unprotected left main artery, or complex 3-vessel disease (SYNTAX score of ≥33)\n4. Informed consent\n\nExclusion Criteria:\n\n1. Subject in cardiogenic shock(need inotrope, pressor or mechanical support to maintain SBP \\>90mmHg)\n2. Presence of moderate to severe aortic insufficiency\n3. Severe peripheral vascular disease\n4. creatinine≥4mg\u002FdL\n5. Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN\n6. History of recent (within 1 month) stroke or TIA\n7. Abnormal coagulation(defined as platelet count ≤50000\u002Fmm3 or Fibrinogen ≤1.50g\u002FL)\n8. Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors, or documented heparin induced thrombocytopenia.",{"count":569,"type":21},176,[53],"The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is :\n\n• If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI",[573,574],"ECMO","High-risk PCI",[573,576],"PCI",{"date":578,"type":34},"2026-05-13",{"date":580,"type":34},"2025-03-21",{"date":582,"type":21},"2026-12-01",{"name":40,"class":41},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":131},"100584152","prediction-of-lvar-and-mace-in-stemi-though-plasma-multiomics-analysis-100584152","NCT06885619","Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis","Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients With Acute ST-segment Elevation Myocardial Infarction Though Plasma Multiomics Analysis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years.\n2. Definite diagnosis of STEMI according to ESC\u002FACC guidelines:\n\n   * Chest pain lasting \\>30 minutes, and\n   * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.\n3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).\n4. First STEMI (no prior history of myocardial infarction).\n5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%.\n6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.\n2. Severe comorbidities:\n\n   * Prior HF (NYHA ≥II);\n   * Severe CKD (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis);\n   * Severe liver disease (Child-Pugh B\u002FC);\n   * Active malignancy (life expectancy \\\u003C1 year);\n   * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding).\n3. Fibrinolysis-followed-by-PCI.\n4. Primary PCI complications:\n\n   * No-reflow\u002Fslow-flow (final TIMI \\\u003C2);\n   * Cardiogenic shock or mechanical complication within 7 days;\n   * In-hospital repeat revascularization.\n5. Inability to complete 6-month follow-up.\n6. Factors affecting blood sampling\u002Fexosome\u002Fimmune\u002Fproteome assays:\n\n   * Blood transfusion within 1 month;\n   * Known hemolytic disorder;\n   * Inadequate venous access.\n7. Pregnancy or lactation.",{"count":117,"type":21},"To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.",[594,595,596,597,598],"Left Ventricular Remodeling","Plasma Multi-Omics","Acute ST-segment Elevation Myocardial Infarction","Immunomics","Major Adverse Cardiovascular Events","2026-05-07",{"date":303,"type":34},{"date":602,"type":34},"2025-05-01",{"date":604,"type":21},"2027-12-31",{"name":40,"class":41},""]